Skip to content

asbestosiscancer.center

Menu
  • asbestosiscancer news
  • Treatment
  • Asbestosis Treatmeant
  • Tipes of Cancer
  • About us
    • Terms and Conditions
    • DMCA
    • Contact
    • Privacy Policy
    • DMCA
Menu

Nykode's VB10.16 therapeutic vaccine shows efficacy in cervical cancer – Clinical Trials Arena

Posted on May 14, 2022 by Asbestosis Cancer Center

Phase II trial results for Nykode Therapeutics’ VB10.16 have shown promise for the use of an HPV and checkpoint combination.
By GlobalData Healthcare
Nykode Therapeutics has announced interim Phase II trial results for its novel therapeutic cancer vaccine VB10.16, in combination with Roche’s anti-PD-L1 Tecentriq (atezolizumab), for the treatment of advanced cervical cancer. VB10.16 is a therapeutic DNA vaccine against human papillomavirus (HPV) 16, designed to stimulate antigen presenting cells (APCs) to produce a long-lasting CD8+ killer T-cell response against cancer cells. Chronic infection with high-risk oncogenic subtypes of HPV is the main etiological factor in cervical carcinogenesis, with HPV detected in almost all cervical cancer cases. HPV 16 is the most common subtype detected in cervical cancer, leading to the development of VB10.16 to stimulate an immune response against the HPV-positive cancer cells.
In the Phase II VB C-02 trial, 39 heavily pretreated cervical cancer patients with HPV 16-positive disease were treated with the VB10.16 and Tecentriq combination. The combination has demonstrated an overall response rate (ORR) of 21%, with two complete responses (CRs) and six partial responses (PRs). A very high disease control rate (DCR) of 64% was also reported, with a median follow-up time of six months. Importantly, anti-tumor activity was reported for both patients with PD-L1-positive (ORR of 27% and DCR of 77%) and PD-L1-negative disease (ORR of 17% and DCR of 58%).
In 2018, Merck & Co.’s anti-PD-1, Keytruda (pembrolizumab), was the first checkpoint inhibitor to receive FDA approval for the second-line treatment of advanced cervical cancer, with an ORR of 14%. The approval was limited to patients with PD-L1 positive disease. Sanofi and Regeneron’s anti-PD-1, Libtayo (cemiplimab), and Agenus’ anti-PD-1, balstilimab, have since demonstrated very similar response rates in this disease setting. Key opinion leaders (KOLs) interviewed by GlobalData found these response rates disappointing and surprising, with the expectation that checkpoint inhibitors would perform well and unleash a strong immune response against the virally induced cancer. KOLs identified combining checkpoint inhibitors with an HPV vaccine as a very promising R&D approach to try to stimulate an anti-HPV-driven immune response. Although cross-trial comparisons must be made with caution, the addition of an HPV vaccine appears to be increasing the response rates beyond that previously reported for single-agent PD-1/PD-L1 inhibition.
While these first Phase II results show promise for the use of an HPV and checkpoint combination, there is stiff competition for patient share in the cervical cancer market. In 2021, a Keytruda plus Herceptin/trastuzumab and chemotherapy combination received FDA approval for first-line use in the PD-L1-positive advanced cervical cancer setting, after showing an OS benefit over Herceptin/trastuzumab and chemotherapy. This means that the majority of patients are likely to be checkpoint inhibitor-exposed in the first line, making them unsuitable candidates for this novel vaccine/PD-L1-inhibitor combination in the second line, with checkpoint inhibitor-exposed patients excluded from this trial.
Related
Furthermore, there are multiple checkpoint inhibitor combinations currently in trials, including Agenus’ balstilimab and zalifrelimab (anti-CTLA-4), Roche’s Tecentriq and tiragolumab (anti-TIGIT), Bristol Myers Squibb’s (BMS’s) relatlimab (anti-LAG-3) and Opdivo (nivolumab, anti-PD-1), and Akeso’s AK104, a bispecific anti-PD-1/CTLA-4 tetrameric antibody. Both Agenus and Akeso have reported impressive response rates in Phase II trials, with an ORR of 32.8% for the balstilimab and zalifrelimab combination and an ORR of 43.8% for AK104. Therefore, it remains to be seen whether combination checkpoint inhibition or a combination of checkpoint inhibition and vaccination provides a superior clinical benefit in the cervical cancer setting.
Contract Manufacturing Organisation and Pharmaceutical Supply Services
Consent and Preference Management Solution for Healthcare Providers
GlobalData exists to help businesses decode the future to profit from faster, more informed decisions.

See also  Hair dye could increase your risk of various forms of cancer - expert warns - Express

source

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Earlier MRI Screenings Could Significantly Cut Breast Cancer Mortality for Certain Pathogenic Variants – Cancer Network
  • Nasopharyngeal Cancer: Causes, Diagnosis, Treatment, and More – Healthline
  • Cerner working with Elligo, Frenome on multiomics for early cancer detection – Healthcare IT News
  • The Pipeline Between Smoking and Bladder Cancer – Newsroom OSF HealthCare
  • Putin appears to grip table during meeting amid cancer rumors – New York Post

Recent Comments

  1. hotshot bald cop on A solution to asbestos waste?
  • Earlier MRI Screenings Could Significantly Cut Breast Cancer Mortality for Certain Pathogenic Variants – Cancer Network
  • Nasopharyngeal Cancer: Causes, Diagnosis, Treatment, and More – Healthline
  • Cerner working with Elligo, Frenome on multiomics for early cancer detection – Healthcare IT News
  • The Pipeline Between Smoking and Bladder Cancer – Newsroom OSF HealthCare
  • Putin appears to grip table during meeting amid cancer rumors – New York Post
  • Asbestosis Treatmeant
  • asbestosiscancer news
  • Tipes of Cancer
  • Treatment

Info

  • Aviso Legal
  • Contact
  • Personalizar Cookies
  • Política de Cookies
  • Política de Privacidad
  • DMCA
  • Terms and Conditions
  • Earlier MRI Screenings Could Significantly Cut Breast Cancer Mortality for Certain Pathogenic Variants – Cancer Network
  • Nasopharyngeal Cancer: Causes, Diagnosis, Treatment, and More – Healthline
  • Cerner working with Elligo, Frenome on multiomics for early cancer detection – Healthcare IT News
  • The Pipeline Between Smoking and Bladder Cancer – Newsroom OSF HealthCare
  • Putin appears to grip table during meeting amid cancer rumors – New York Post

Mesothelioma Nutrition & NourishmentASBESTOSIS CANCER CENTER

▶️ Mesothelioma Nutrition & Nourishment When facing cancers cells such as mesothelioma, a well-balanced diet is a necessary facet of assisting your body. Investigation reveals that 80-90 percent of all cancers are due to environmental factors, and of these, 30-40 percent are directly connected to diet.

Alterations In The Psychosocial Health Of Individuals Affected By Asbestos PoisoningASBESTOSIS CANCER CENTER

▶️ Alterations In The Psychosocial Health Of Individuals Affected By Asbestos Poisoning One hundred and eighty patients got involved, with 110 constant individuals affected by breathing diseases created through asbestos poisoning and 70 healthy subjects of the same age group. All the individuals were male.

©2022 | Built using WordPress and Responsive Blogily theme by Superb
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT